Anna Moseley

Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa

Also affiliated with Fred Hutch Cancer Center

MedicineEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 14 papers. Top paper: “Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia”.

Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia

Blood Advances(2022)10.1182/bloodadvances.2022008216

N/A

1.8DataRank · unranked

72 citations

Anna Moseley, Kristen M. O’Dwyer, Brent L. Wood, Jae H. Park, Matthew J. Wieduwilt +12 more

A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013

Journal of Patient-Reported Outcomes(2020)10.1186/s41687-020-00220-x

N/A

0DataRank · unranked

5 citations

Joseph M. Unger, James L. Wade, Lynne I. Wagner, Mario E. Lacouture, Keisha C. Humphries +15 more

Predictive model of aromatase inhibitor non-adherence using patient-reported outcomes in women with breast cancer (SWOG S1105).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.12019

N/A

0DataRank · unranked

3 citations

Anna Moseley, Kathryn B. Arnold, Grace Clarke Hillyer, Julie R. Gralow, N. Lynn Henry +4 more

AML Risk Stratification Models Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Research Square(2020)10.21203/rs.3.rs-24023/v1

N/A

0DataRank · unranked

3 citations

Anna Moseley, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, I-Ming L. Chen +17 more

Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors

JNCI Journal of the National Cancer Institute(2021)10.1093/jnci/djab022

N/A

0DataRank · unranked

26 citations

Alfred I. Neugut, Anna Moseley, Kathryn B. Arnold, Julie R. Gralow, N. Lynn Henry +4 more

Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203

Leukemia & lymphoma/Leukemia and lymphoma(2021)10.1080/10428194.2021.1881512

N/A

0DataRank · unranked

2 citations

Megan Othus, Guillermo Garcia‐Manero, Frederick R. Appelbaum, Harry P. Erba, Roland B. Walter +1 more

Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL study (SWOG S1925, NCT#04269902).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps7567

N/A

0DataRank · unranked

3 citations

Anna Moseley, Brian T. Hill, John M. Pagel, Mazyar Shadman, Michael Fisch +9 more

A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

Leukemia & lymphoma/Leukemia and lymphoma(2022)10.1080/10428194.2022.2148212

N/A

0DataRank · unranked

14 citations

Laura C. Michaelis, Megan Othus, Annette E. Hay, Roland B. Walter, Meagan A. Jacoby +15 more

Survival outcomes by insurance status for patients with cancer ages 18-64 and 65 or older treated in clinical trials.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.28_suppl.154

N/A

0DataRank · unranked

1 citations

Anna Moseley, Riha Vaidya, Hong Xiao, Michael LeBlanc, Dawn L. Hershman +1 more

Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients

Biomarker Research(2023)10.1186/s40364-023-00461-0

N/A

0DataRank · unranked

4 citations

Xing Hua, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, Harry P. Erba +14 more

Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network

Haematologica(2023)10.3324/haematol.2023.282733

N/A

0DataRank · unranked

2 citations

Anna Moseley, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, Harry P. Erba +10 more

Proteogenomic characterization of highly enriched viable leukemic blasts in acute myeloid leukemia: A SWOG report

eJHaem(2024)10.1002/jha2.1041

N/A

0DataRank · unranked

0 citations

Megan Othus, Chenwei Lin, Melinda A. Biernacki, Marie Bleakley, Thomas R. Chauncey +20 more

Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia

JCO Oncology Practice(2020)10.1200/jop.19.00133

N/A

0DataRank · unranked

23 citations

Megan Othus, Guillermo Garcia‐Manero, Min Fang, Jerald P. Radich, David A. Rizzieri +24 more

Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trials

Clinical Trials(2025)10.1177/17407745241304065

N/A

0DataRank · unranked

2 citations

Michael LeBlanc, Boris Freidlin, Rory M. Shallis, Amer M. Zeidan, David A. Sallman +4 more